References

Aranjo, F. G., Lin, T, and Remington, J. S. (1993). The activity of atovaquone in murine toxoplasmosis is markedly augmented when used in combination with pyrimethanine or sulphadiazine. J. Infect. Dis., 167(2), 494-497.

Berlanger, F., Derouin, F., Grangeot-Keros, L., et al. (1999). Incidence and risk factors of toxoplasmosis in a cohort of HIV infected patients 1988-1996. Clin. Infect. Dis., 28, 575-581. Briggs, G. G, Freeman, R. K., and Yaffe, S. J. (eds) (1994). Drugs in pregnancy and lactation. Williams & Wilkins, Baltimore, MD.

Couvreur, J., Desmonts, G., and Thulliez, Ph. (1988). Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J. Antimicrob. Chemother., 22(Suppl. B), 193-200. Derouin, F. and Chastang, C. (1989). In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob. Agents Chemother., 33, 1753-1759.

Derouin, F. (2000). Drugs effective against Toxoplasma gondii. Present status and future perspective. In: Congenital toxoplasmosis (P. Ambroise-Thomas and E. Petersen, eds). Springer-Verlag, France, pp. 94-110.

Desmonts, G. and Couvreur, J. (1984). Toxoplasmose congenitale. Etude prospective del'issue de la grossesse chez 542 femmes atteintes de toxoplasmose acquise en cours de gestation. Ann. Pediat., 31, 805-809.

Dutton, G. N. (1989a). Toxoplasmic chorioretinitis. Ann. Acad. Med., 18, 214-221. Dutton, G. N. (1989b). Recent developments in the prevention and treatment of congenital toxoplasmosis. Int. Ophtalmol., 13, 407-413.

Gilbert, R. E., Dunn, D. T., Wallon, M., et al. (2001). Ecological comparison of the risks of mother to child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol. Infect., 127, 113-20.

Farthing, C., Rendel, M., Curriet, B., et al. (1992). Azithromycin for cerebral xoplasmosis. Lancet, 339, 437-438.

Forestier, F., Daffos, F., Rainaut. et al. (1987). Suivi therapeutique foetomaternel de la spiramycine en cours de grosesse. Arch. Fr. Ped., 44, 539-544.

Foulon, W., Villena, I., Stray-Pedersen, B. et al. (1999). Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at one year of age. Am. J. Obstet. Gynecol., 180, 410-415.

Haverkos, H. W. (1987). Assessment of therapy for toxoplasma encephalitis. The TE study group. Am. J. Med., 292, 1108-1112.

Hohlfeld, J., Daffos, F., Thulliez, P., et al. (1989). Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J. Pediatr., 115, 765-769.

Hugues, W., Dorenbaum, A., Yogev, R. et al. (1998). Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficient virus infected infants and children. Antimicrob. Agents Chemother., 42, 1315-1318.

Huskinson, M. J., Aranjo, F. G., and Remington, J. S. (1991). Evaluations of the effect of

Toxoplasma gondii. J. Infect. Dis., 164, 170-177.

Jeddi, A., Azaiez, A., Bouguila, H. et al. (1997). Value of clindamycin in treatment of ocular toxoplasmosis. J. Fr. Ophtalmol., 20, 418-422.

Joss, A. W. L. (1992). Treatment. In: Human toxoplasmosis (D. O. Ho-Yen, and A. W. L. Joss, eds). Oxford University Press, New York, pp. 119-143.

Kovacs, J. A. (1992). Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS.

Lancet, 340, 637-638.

Lackanpal, V., Schocket, S. S., and Nirankari, V. S. (1983). Clindamycin in the treatment of toxoplasmic retinochoroiditis. Am. Ophtalmol., 95, 605-613.

Lancet Editorial (1983). Pyrimethamine combination in pregnancy. Lancet, 2, 1005-1007. Leport, C. and Raguin, G. (1990). Toxoplasmic encephalitis. Curr. Opin. Infect. Dis., 3, 614-619. Leport, C., Chene, G., Morlat, P., et al. (1996). Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immmunodeficiency virus infection: a double-blind, randomized trial. J. Infect. Dis., 173(1), 91-97.

Page 271

Luft, B. J. and Hafner. R. (1990). Toxoplasmic encephalitis. AIDS, 4, 593-595. Maisonneuve, H., Faber, C., Piens, M.A. et al. (1984) Toxoplasmose congenitale. Tolerance de l'association sulfadoxine-pyrimethamine. Vingt quatre observations. Press. Med., 13(14), 859-862. Mariuz, P., Bosler, E. M., and Luft, B. J. (1994). Toxoplasmosis in individuals with AIDS. Infect. Dis. Clin. N. Am., 8, 365-381.

McAuley, J., Boyer, K. M., Patel, D. et al. (1994). Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago collaborative treatment trial. Clin. infect. Dis., 18, 38-72.

McCabe R. E. and Oster, S. (1989). Current recommendations and future prospects in the treatment of toxoplasmosis. Drugs, 38, 973-987.

McGee, T., Wolters, C., Stein, L. et al. (1992). Absence of sensorineural hearing loss in treated infants and children with congenital toxoplasmosis. Otolaryngology, 106, 75-80.

McLeod, R., Boyer, K. and the Toxoplasmosis Study groups and Collaborators (2000). Management of and outcome for the newborn infant with congenital toxoplasmosis. In: Congenital toxoplasmosis

(P. Ambroise-Thomas and E. Petersen, eds). Springer-Verlag, France, pp. 189-213.

Mets, M. B., Holfels, E., Boyer, K. M. et al. (1996). Eye manifestations in congenital toxoplasmosis.

Nguyen B. T. and Stadtsbader, S. (1985). Comparative effect of cotrimoxazole and spiramycin in pregnant mice infected with Toxoplasma gondii. Br. J. Pharmacol., 85, 713-716. Petersen, E. and Eaton, R. B. (2000). Neonatal screening for congenital infection with Toxoplasma gondii. In: Congenital toxoplasmosis (P. Ambroise-Thomas and E. Petersen, eds). Springer-Verlag, France, pp. 306-311.

Piens, M. A. and Garin, J. P. (1989). New perspective in the chemoprophylaxis of toxoplasmosis. J. Chemother, 3, 614-619.

Piketty, C., Derouin, F., Rouveix, B. et al. (1990). In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.

Antimicrob. Agents Chemother., 34, 1467-1472.

Rothova, A., Bitenhuis, H. J., Meenken, C. et al. (1989). Therapy of ocular toxoplasmosis. Int. Ophtalmol., 13, 415-419.

Torre, D., Casari, S., Speranza, F. et al. (1998). Randomised trial of trimetoprim-sulfamethxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS.

Antimicrob. Agents Chemother., 42, 1346-1349.

Torres, R. A., Weinberg, W., Stansell, A. et al. (1997). Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis., 24, 422-429. Sheffield, H. G. and Melton, M. L. (1975). Effect of pyrimethamine and sulphadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. J. Parasitol., 61, 704-712. Stray-Pedersen, B. and Foulon, W. (2000). Effect of treatment of the infected pregnant women and her fetus. In: Congenital toxoplasmosis (P. Ambroise-Thomas and E. Petersen, eds). Springer-Verlag, France, pp. 141-152.

Stray-Pedersen, B. (1993). Toxoplasmosis in pregnancy. In: Infectious diseases. Challenges for the

1990s. (G. L. Gilbert, ed.). Balliere's Clinical Obstetrics and Gynecology. Vol. 17, 1. Bailliere Tindall, London, pp. 107-137.

Stray-Pedersen, B. and The European Research Network of Congenital Toxoplasmosis Treatment Group (1996). Azitromycin levels in placental tissue, amniotic tissue and blood. In Abstract book, of the 36th ICAAC American Society for Microbiology, New Orleans, 15-18 September 1996. Wilson, C. B., Remington, J. S., Stagno, S. et al. (1980). Development of adverse sequelae in children born with subclinical Toxoplasma infection. Pediatrics, 66, 767-774. WHO (1988). Report of the WHO consultation on public health aspects of toxoplasmosis. WHO/ CDS/VPH 74, pp. 2-14.

WHO (1990). WHO model prescribing information - drugs used in parasitic diseases, pp. 53-60.

0 0

Post a comment